Physician profile
Michael Brener
NPI 1992075451
$146,095.99
in general payments reported to CMS, 2019-2025
23 companies · $2,125 in 2025
The $2,125 reported for 2025 was more than what 84% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,079 · 2020: $258 · 2021: $26K · 2022: $2,316 · 2023: $54K · 2024: $60K · 2025: $2,125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $100K · Travel and Lodging: $13K · Food and Beverage: $3,742 · Education: $1.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $100,000.00 |
| Travel and Lodging | $12,690.26 |
| Food and Beverage | $3,742.40 |
| Education | $1.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $102,501.26 | 2021-2025 | Sapien 3 Ultra Resilia |
| Merck Sharp & Dohme LLC | $25,000.00 | 2021 | |
| Abiomed | $9,022.87 | 2021-2024 | Impella |
| Ancora Heart, INC. | $3,351.70 | 2022-2023 | Accucinch |
| Medtronic, INC. | $1,825.26 | 2022-2025 | Corevalve Evolut R, Onyx Frontier, Ffrangio |
| Abbott Laboratories | $1,573.61 | 2020-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Mitraclip, Cardiomems |
| Astrazeneca Pharmaceuticals LP | $770.62 | 2019-2021 | |
| Boston Scientific Corporation | $403.19 | 2021-2024 | Avvigo Guidance System |
| Astellas Pharma US INC | $279.97 | 2021-2022 | |
| Heartflow, INC. | $246.68 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $188.33 | 2019-2021 | |
| Chiesi USA, INC. | $167.28 | 2022-2023 | Kengreal |
| Janssen Pharmaceuticals, INC | $124.95 | 2022 | |
| Pfizer INC. | $120.76 | 2019 | |
| Cardiovascular Systems INC. | $120.20 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cathworks, INC. | $84.12 | 2023 | Ffrangio |
| Novartis Pharmaceuticals Corporation | $64.18 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.07 | 2021-2024 | Jardiance |
| Penumbra, INC. | $63.06 | 2023 | Indigo System |
| Livanova USA, INC. | $50.27 | 2023 | Protekduo |
| Teleflex LLC | $38.00 | 2024 | Manta |
| E.R. Squibb & Sons, L.L.C. | $20.85 | 2022 | |
| Sanofi-Aventis U.S. LLC | $14.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Brener listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.